Longwood Capital Partners »

Erasca shares owned by Longwood Capital Partners

Quarter-by-quarter ownership of Erasca (ERAS) shares owned by Longwood Capital Partners from 13F filings

Historical chart of Longwood Capital Partners investment in Erasca

Tip: Access up to 7 years of quarterly data

All positions including Erasca held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Erasca by Longwood Capital Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $5.7M 355k 16.18

More positions owned by Longwood Capital Partners

Ideaya Biosciences Call Call Option (IDYA)
Praxis Precision Medicines I Com New (PRAX)
Terns Pharmaceuticals (TERN)
Aadi Bioscience (WHWK)
Tango Therapeutics (TNGX)
Bright Minds Biosciences Com New (DRUG)
Sutro Biopharma (STRO)
Erasca (ERAS)
Surrozen Com New (SRZN)
Ocular Therapeutix (OCUL)
Compass Therapeutics (CMPX)
Minerva Neurosciences Com New (NERV)
Moonlake Immunotherapeutics Class Ord A (MLTX)
Argen Se - Sponsored Adr (ARGX)
Oculis Holding Ordinary Shares (OCS)

View all positions for Longwood Capital Partners

Top funds holding Erasca

Frazier Life Sciences Management
BlackRock
VR Adviser
T. Rowe Price Investment Management
Vanguard Group
Vivo Capital
Vanguard Capital Management
Logos Global Management
Paradigm Biocapital Advisors
Siren
Arch Venture Corp
State Street Corporation
Geode Capital Management
Cormorant Asset Management
Balyasny Asset Management

View all funds holding Erasca